Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternative

被引：0
|
作者：
Hammoudi, N. [1 ]
Hassid, D. [1 ]
Bonnet, J. [1 ]
Minh, M. L. Tran [1 ]
Baudry, C. [1 ]
Chedouba, L. [1 ]
Vauthier, A. [1 ]
Gornet, J. M. [1 ]
Allez, M. [1 ]
机构：
[1] APHP St Louis, Gastroenterol, Paris, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P515
引用
收藏
页码：643 / 643
页数：1
相关论文
共 50 条
  • [21] Rapid Infliximab Infusions Are Safe and Well Tolerated in Inflammatory Bowel Disease Patients
    Raza, Ali
    Gudsoorkar, Vineet
    Abraham, Bincy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S265 - S265
  • [22] Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
    Kolar, M.
    Duricova, D.
    Bortlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M., Jr.
    Lukas, Milan
    DIGESTIVE DISEASES, 2017, 35 (1-2) : 91 - 100
  • [23] SERUM INFLIXIMAB LEVELS,ANTIBODIES TO INFLIXIMAB AND ALBUMIN CONCENTRATIONS DURING INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    Malickova, K.
    Janatkova, I.
    Duricova, D.
    Bortlik, M.
    Lukas, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 213 - 213
  • [24] Complementary and Alternative Medicine in Brazilian Patients With Inflammatory Bowel Diseases
    Debora, Henriques
    Julio, Baima
    Jaqueline, de Barros
    Jeslei, Vanni
    Rebeca, Oliveira
    Henrique, Lima
    Jean, Otiti
    Fabio, Neves
    Ligia, Sassaki
    Cyrla, Zaltman
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S23 - S23
  • [25] Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases
    Cheifetz, Adam S.
    Gianotti, Robert
    Luber, Raphael
    Gibson, Peter R.
    GASTROENTEROLOGY, 2017, 152 (02) : 415 - +
  • [26] Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe
    Kolar, Martin
    Duricova, Dana
    Bortlik, Martin
    Hruba, Veronika
    Machkova, Nadezda
    Mitrova, Katarina
    Malickova, Karin
    Lukas, Martin
    Lukas, Milan
    GASTROENTEROLOGY, 2016, 150 (04) : S416 - S416
  • [27] The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases
    Bothorel, L.
    Laharie, D.
    Poullenot, F.
    Gohier, E.
    Chevrier, C.
    Berger, A.
    Zerbib, F.
    Riviere, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1490 - I1490
  • [28] ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases
    Jung, Eun Suk
    Choi, Ko-Woon
    Kim, Seung Won
    Huebenthal, Matthias
    Mucha, Soeren
    Park, Jihye
    Park, Zewon
    Ellinghaus, David
    Schreiber, Stefan
    Franke, Andre
    Oh, Woo Yong
    Cheon, Jae Hee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (10) : 1727 - 1735
  • [29] Early Discontinuation of Infliximab During Pregnancy Reduces Neonatal Exposure to Infliximab and is Safe for the Inflammatory Bowel Disease Patients
    Zelinkova, Zuzana
    van der Ent, Cokkie
    Bruin, Karlien F.
    van Baalen, Onno
    Vermeulen, Hestia G.
    Smalbraak, Hermen J.
    Ouwendijk, Rob J.
    Hoek, Aad C.
    van der Werf, S. D.
    Kuipers, Ernst J.
    van der Woude, Christien J.
    GASTROENTEROLOGY, 2012, 142 (05) : S385 - S385
  • [30] Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
    Kolar, M.
    Duricova, D.
    Brotlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M.
    Lukas, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S45 - S46
12345